---
title: "VRTX Analyst Ratings and Price Target - Vertex Stock Forecast | Tradytics"
description: "Vertex (VRTX) analyst ratings, the average price target and its range, and every firm's latest call."
url: "https://tradytics.com/research/VRTX/analysts"
image: "https://tradytics.com/api/v2/og/research.png?id=VRTX&v=stock-11994867"
---

# VRTX analyst estimates

Vertex (VRTX) analyst ratings, the average price target and its range, and every firm's latest call.

- 24 firms rate VRTX: 21 buy, 2 hold, 1 sell.
- The average price target is $579.29 from None analysts, from $350.00 to $665.00.

## VRTX analyst ratings and price targets

| Date | Firm | Call | Target |
| --- | --- | --- | --- |
| Nov 3, 2026 | TD Cowen | Vertex (VRTX) PT Raised to $575 at TD Cowen | $575.00 |
| Nov 3, 2026 | Wells Fargo | Vertex (VRTX) PT Raised to $650 at Wells Fargo | $650.00 |
| Nov 3, 2026 | J.P. Morgan | Vertex (VRTX) PT Raised to $570 at JPMorgan | $570.00 |
| Nov 3, 2026 | Cantor Fitzgerald | Vertex (VRTX) PT Raised to $619 at Cantor Fitzgerald | $619.00 |
| Oct 8, 2026 | RBC Capital | Vertex Pharmaceuticals price target raised to $576 from $570 at RBC Capital | $576.00 |
| Sep 28, 2026 | UBS | Vertex Pharmaceuticals price target raised to $615 from $585 at UBS | $615.00 |
| Sep 23, 2026 | Jefferies | Vertex (VRTX) PT Raised to $640 at Jefferies | $640.00 |
| Sep 22, 2026 | H.C. Wainwright | H.C. Wainwright Reiterates Buy Rating on Vertex (VRTX) | $641.00 |
| Sep 1, 2026 | Goldman Sachs | Vertex Pharmaceuticals added to US Conviction List at Goldman Sachs | $653.00 |
| Sep 1, 2026 | Morgan Stanley | Vertex Pharmaceuticals resumed with an Overweight at Morgan Stanley | $665.00 |
| Aug 11, 2026 | Bernstein | Bernstein SocGen Reiterates Outperform Rating on Vertex (VRTX) | $608.00 |
| Aug 10, 2026 | Wolfe Research | Vertex (VRTX) PT Raised to $562 at Wolfe Research | $562.00 |
| Aug 5, 2026 | Barclays | Vertex Pharmaceuticals price target raised to $617 from $615 at Barclays | $617.00 |
| Aug 5, 2026 | Truist Financial | Vertex Pharmaceuticals price target raised to $565 from $560 at Truist | $565.00 |
| Aug 4, 2026 | Cantor Fitzgerald | Vertex Pharmaceuticals price target raised to $595 from $590 at Cantor Fitzgerald | $595.00 |

- [VRTX stock analysis](https://tradytics.com/research/VRTX)
- [VRTX options overview](https://tradytics.com/research/VRTX/options)
- [VRTX earnings](https://tradytics.com/research/VRTX/earnings)
- [VRTX financials](https://tradytics.com/research/VRTX/financials)
- [VRTX peer analysis](https://tradytics.com/research/VRTX/peers)
- [VRTX insider trading](https://tradytics.com/research/VRTX/insiders)
- [VRTX congressional trades](https://tradytics.com/research/VRTX/politicians)
- [VRTX institutional holdings](https://tradytics.com/research/VRTX/funds)
- [VRTX live chart](https://tradytics.com/charts?s=VRTX)
- [Read the data without JavaScript](https://tradytics.com/research/VRTX/analysts?snapshot=1)
